国际医药卫生导报2025，Vol.31Issue(11)：1791-1795,5.DOI:10.3760/cma.j.cn441417-20241128-11006
地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析
Analysis of the effects of Di'ao Xinxuekang Capsules combined with diltiazem on clinical symptoms and serum cytokine levels in patients with angina pectoris of coronary heart disease
摘要
Abstract
Objective To analyze the efficacy of Di'ao Xinxuekang Capsules combined with diltiazem in the treatment of angina pectoris of coronary heart disease.Methods A total of 96 patients with angina pectoris of coronary heart disease who were admitted to the First People's Hospital of Zhumadian from March 2022 to July 2024 were selected as the study subjects.According to the treatment plan,the patients were divided into the control group(49 cases)and the study group(47 cases).There were 20 males and 29 females in the control group,aged 54-70(61.97±3.35)years,course of the disease 5-15(10.24±1.96)months.There were 19 males and 28 females in the study group,aged 53-70(62.08±3.46)years,course of the disease 5-16(10.31±1.89)months.The control group was treated with diltiazem,while the study group was treated with Di'ao Xinxuekang capsules in addition to the treatment of the control group.Both groups received continuous treatment for 3 months.Compare the therapeutic effects and adverse reactions of the two groups,as well as the clinical symptoms(frequency and duration of angina pectoris attacks),cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD)],and levels of serum-related cytokines[serum N-terminal pro-B-type natriuretic peptide(NT-proBNP),cardiac troponin I(cTnI),high-sensitivity C-reactive protein(hs-CRP)levels,and the ratio of neutrophils to lymphocytes(NLR)]before and after treatment.Independent sample t test,paired t test,and x2 test were used for statistical analysis.Results The total effective rate of the study group was higher than that of the control group[95.75％(45/47)vs.77.55％(38/49)](P＜0.05).After treatment,the frequency of angina pectoris attacks in the study group was lower than that in the control group[(2.30±0.49)times/week vs.(3.22±0.51)times/week],and the duration was shorter than that in the control group[(3.22±0.71)min/time vs.(4.61±0.85)min/time](both P＜0.05);the LVEF of the study group was higher than that of the control group[(48.02±0.61)％vs.(45.91±0.52)％],and the LVESD was lower than that of the control group[(40.15±2.98)mm vs.(44.05±3.07)mm](both P＜0.05);the levels of serum NT-proBNP,cTnl,hs-CRP and NLR in the study group were all lower than those in the control group[(246.51±29.52)ng/L vs.(378.54±31.74)ng/L,(0.20±0.04)μg/L vs.(0.39±0.05)μg/L,(3.05±0.74)mg/L vs.(4.65±0.92)mg/L,1.98±0.35 vs.2.61±0.39](all P＜0.05).The comparison of the total incidence rates of adverse reactions between the two groups showed no statistically significant difference(P＞0.05).Conclusion The combination of Di'ao Xinxuekang Capsules and diltiazem is effective in treating angina pectoris of coronary heart disease.It can inhibit the occurrence of angina pectoris,reduce inflammatory responses,improve cardiac function,and alleviate the degree of myocardial damage.It also has good safety.关键词
冠心病/心绞痛/地奥心血康胶囊/地尔硫卓Key words
Coronary heart disease/Angina pectoris/Di'ao Xinxuekang Capsules/Diltiazem引用本文复制引用
金兴山,杨莉..地奥心血康胶囊联合地尔硫卓对冠心病心绞痛患者临床症状及血清相关细胞因子水平的影响分析[J].国际医药卫生导报,2025,31(11):1791-1795,5.基金项目
2024年度河南省中医药科学研究专项课题(2024ZY2206) Special Subject of TCM Scientific Research in Henan Province in 2024(2024ZY2206) （2024ZY2206）
